Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248) is a protein found on tumor vasculature and in tumor stroma. Here, we tested whether TEM1 has potential as a therapeutic target for cancer immunotherapy by immunizing immunocompetent mice with
John G. Facciponte, Stefano Ugel, Francesco De Sanctis, Chunsheng Li, Liping Wang, Gautham Nair, Sandy Sehgal, Arjun Raj, Efthymia Matthaiou, George Coukos, Andrea Facciabene
Title and authors | Publication | Year |
---|---|---|
Pan-cancer analysis identified CD248 as a potential target for multiple tumor types
Guo L, Liao Y, Zhang X, Guo R, Wang Z, Yang D |
Frontiers in Pharmacology | 2025 |
Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches
Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X, Han D, Xu C, Liu S, Yang F, Qin W, Wen W |
Theranostics | 2024 |
Group XIV C-type lectins: emerging targets in tumor angiogenesis.
Yee EJ, Vigil I, Sun Y, Torphy RJ, Schulick RD, Zhu Y |
Angiogenesis | 2024 |
Probiotic-derived amphiphilic exopolysaccharide self-assembling adjuvant delivery platform for enhancing immune responses
Sheng S, Zhang H, Li X, Chen J, Wang P, Liang Y, Li C, Li H, Pan N, Bao X, Liu M, Zhao L, Li X, Guan P, Wang X |
Journal of nanobiotechnology | 2024 |
Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?
Tadic S, Martínez A |
Frontiers in immunology | 2024 |
Personalized nanovaccines for treating solid cancer metastases
Feng T, Hu J, Wen J, Qian Z, Che G, Zhou Q, Zhu L |
Journal of Hematology & Oncology | 2024 |
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
Chen J, Sobecki M, Krzywinska E, Thierry K, Masmoudi M, Nagarajan S, Fan Z, He J, Ferapontova I, Nelius E, Seehusen F, Gotthardt D, Takeda N, Sommer L, Sexl V, Münz C, DeNardo D, Hennino A, Stockmann C |
EMBO Molecular Medicine | 2024 |
Vasculature organotropism in drug delivery
Amruta A, Iannotta D, Cheetham SW, Lammers T, Wolfram J |
Advanced Drug Delivery Reviews | 2023 |
Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production
Bayart C, Mularoni A, Hemmani N, Kerachni S, Jose J, Gouet P, Paladino J, Le Borgne M |
Pharmaceuticals | 2022 |
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang Y, Brekken RA |
Journal of leukocyte biology | 2022 |
Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies
Caligola S, De Sanctis F, Canè S, Ugel S |
Frontiers in Genetics | 2022 |
Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens
Zhang SW, Wang H, Ding XH, Xiao YL, Shao ZM, You C, Gu YJ, Jiang YZ |
2022 | |
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
ZR Huinen, EJ Huijbers, JR van Beijnum, P Nowak-Sliwinska, AW Griffioen |
Nature Reviews Clinical Oncology | 2021 |
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
S Pierini, A Mishra, R Perales-Linares, M Uribe-Herranz, S Beghi, A Giglio, S Pustylnikov, F Costabile, S Rafail, A Amici, JG Facciponte, C Koumenis, A Facciabene |
Journal for ImmunoTherapy of Cancer | 2021 |
The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
K Zhang, C Xu, S Liu, Y Jiang, X Zhao, S Ma, Y Li, F Yang, Y Wang, P Meng, C Shi, D Han, W Wen, W Qin |
Frontiers in Oncology | 2021 |
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1
JK Fierle, M Brioschi, M de Tiani, L Wetterwald, V Atsaves, J Abram-Saliba, TV Petrova, G Coukos, SM Dunn |
Reproduction | 2021 |
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer
Efthymia-Iliana Matthaiou, Yi Guo, Jaleh Barar, Raphael Sandaltzopoulos, Lana E Kandalaft, Chunsheng Li, George Coukos, Yadollah Omidi |
BioImpacts : BI | 2021 |
CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma
S Liu, C Xu, K Zhang, D Han, F Yang, Y Li, X Zhao, S Ma, H Li, S Lu, T Lu, J Zhang, W Qin, W Wen, B Yang |
Annals of translational medicine | 2021 |
Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target
Stefano Pierini, Janos L. Tanyi, Fiona Simpkins, Erin George, Mireia Uribe-Herranz, Ronny Drapkin, Robert A Burger, Mark A Morgan, Andrea Facciabene |
JCI Insight | 2020 |
Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
CH Pai, SR Lin, CH Liu, SY Pan, H Hsu, YT Chen, CT Yen, IS Yu, HL Wu, SL Lin, SW Lin |
Scientific Reports | 2020 |
CD248 as a novel therapeutic target in pulmonary arterial hypertension
T Xu, L Shao, A Wang, R Liang, Y Lin, G Wang, Y Zhao, J Hu, S Liu |
Clinical and Translational Medicine | 2020 |
Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancer—A Preliminary Study
Ł Pietrzyk, P Wdowiak |
Cancer control : journal of the Moffitt Cancer Center | 2020 |
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
A von Witzleben, C Wang, S Laban, N Savelyeva, CH Ottensmeier |
Cells | 2020 |
C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation
KA Khan, JL McMurray, F Mohammed, R Bicknell |
The FEBS journal | 2019 |
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors
T Doi, T Aramaki, H Yasui, K Muro, M Ikeda, T Okusaka, Y Inaba, K Nakai, H Ikezawa, R Nakajima |
Investigational New Drugs | 2019 |
CD248: A therapeutic target in cancer and fibrotic diseases
BA Teicher |
Oncotarget | 2019 |
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium
Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT |
Cancer journal (Sudbury, Mass.) | 2019 |
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
KA Khan, RS Kerbel |
Nature Reviews Clinical Oncology | 2018 |
Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression
Z Tan, L Liu, MS Chiu, KW Cheung, CW Yan, Z Yu, BK Lee, W Liu, K Man, Z Chen |
OncoImmunology | 2018 |
Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors
AG Lin, B Xiang, DJ Merlino, TR Baybutt, J Sahu, A Fridman, AE Snook, V Miller |
OncoImmunology | 2018 |
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
KP Fabian, N Chi-Sabins, JL Taylor, R Fecek, A Weinstein, WJ Storkus |
OncoImmunology | 2017 |
Trial Watch: DNA-based vaccines for oncological indications
S Pierini, R Perales-Linares, M Uribe-Herranz, JG Pol, L Zitvogel, G Kroemer, A Facciabene, L Galluzzi |
OncoImmunology | 2017 |
Local Endothelial Complement Activation Reverses Endothelial Quiescence, Enabling T-cell Homing and Tumor Control during T-cell Immunotherapy
A Facciabene, FD Sanctis, S Pierini, ES Reis, K Balint, J Facciponte, J Rueter, M Kagabu, P Magotti, E Lanitis, RA DeAngelis, RJ Buckanovich, WC Song, JD Lambris, G Coukos |
OncoImmunology | 2017 |
Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine
SC Wagner, TE Ichim, V Bogin, WP Min, F Silva, AN Patel, S Kesari |
Oncotarget | 2017 |
Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.
Fabian KL, Storkus WJ |
Advances in experimental medicine and biology | 2017 |
Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates
Ł Pietrzyk |
Disease Markers | 2016 |
Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors
Y Zhang, HC Ertl |
Oncotarget | 2016 |
Safety of targeting tumor endothelial cell antigens
SC Wagner, NH Riordan, TE Ichim, J Szymanski, H Ma, JA Perez, J Lopez, JJ Plata-Munoz, F Silva, AN Patel, S Kesari |
Journal of Translational Medicine | 2016 |
Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies
DJ OShannessy, H Dai, M Mitchell, S Huntsman, S Brantley, D Fenstermacher, DR Reed |
Sarcoma | 2016 |
Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage
C Mogler, M Wieland, C Konig, J Hu, A Runge, C Korn, E Besemfelder, K Breitkopf-Heinlein, D Komljenovic, S Dooley, P Schirmacher, T Longerich, HG Augustin |
EMBO Molecular Medicine | 2015 |
Targeting the tumor vasculature to enhance T cell activity
E Lanitis, M Irving, G Coukos |
Current Opinion in Immunology | 2015 |
Targeting tumor vasculature: expanding the potential of DNA cancer vaccines
S Ugel, JG Facciponte, FD Sanctis, A Facciabene |
Cancer Immunology, Immunotherapy | 2015 |
Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™
TE Ichim, S Li, H Ma, YV Yurova, JS Szymanski, AN Patel, S Kesari, WP Min, SC Wagner |
Journal of Translational Medicine | 2015 |
Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease
J Falconer, CD Buckley |
Nature Reviews Rheumatology | 2015 |
Trial watch: Naked and vectored DNA-based anticancer vaccines
N Bloy, A Buqué, F Aranda, F Castoldi, A Eggermont, I Cremer, C Sautès-Fridman, J Fucikova, J Galon, R Spisek, E Tartour, L Zitvogel, G Kroemer, L Galluzzi |
OncoImmunology | 2015 |
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma
M Mazzocco, M Martini, A Rosato, E Stefani, A Matucci, SD Santa, FD Sanctis, S Ugel, S Sandri, G Ferrarini, T Cestari, S Ferrari, P Zanovello, V Bronte, S Sartoris |
Immunology | 2015 |
Cancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?
SC Wagner, TE Ichim, H Ma, J Szymanski, JA Perez, J Lopez, V Bogin, AN Patel, FM Marincola, S Kesari |
Journal of Translational Medicine | 2015 |